Ocuphire Pharma Starts Mid-Stage APX3330 Study In Diabetic Retinopathy Patients

  • Ocuphire Pharma Inc OCUP has screened the first patient in Phase 2 ZETA-1 trial evaluating APX3330 in non-proliferative diabetic retinopathy (NPDR) and mild proliferative diabetic retinopathy (mild PDR).
  • Effects on diabetic macular edema will be explored as a secondary outcome.
  • APX3330 is a small molecule oral drug candidate and a first-in-class inhibitor of the transcription factor regulator Ref-1 (reduction-oxidation effector factor-1).
  • APX3330 blocks the downstream pathways regulated by Ref-1, including angiogenesis (VEGF) and inflammation (NF-kB), to decrease abnormal activation of both angiogenesis and inflammatory pathways.
  • The 100-subject trial is designed to evaluate the efficacy of APX3330 to improve diabetic retinopathy over 24 weeks.
  • The study's primary endpoint will evaluate the percentage of subjects with a more than 2 step improvement on the Diabetic Retinopathy Severity Scale score.
  • Secondary endpoints include evaluating central subfield thickness to assess effects on diabetic macular edema, BCVA, safety, and tolerability.
  • Price Action: OCUP shares are down 3.07% at $5.68 on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareFDAGeneralBriefsDiabetesPhase 2 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!